{"id":"https://openalex.org/W2582299884","doi":"https://doi.org/10.1182/blood.v120.21.4330.4330","title":"FLAG \u00b1 Idarubicin Compared with 7+3 As Initial Induction for Secondary Acute Myeloid Leukemia: A Single Institution Experience","display_name":"FLAG \u00b1 Idarubicin Compared with 7+3 As Initial Induction for Secondary Acute Myeloid Leukemia: A Single Institution Experience","publication_year":2012,"publication_date":"2012-11-16","ids":{"openalex":"https://openalex.org/W2582299884","doi":"https://doi.org/10.1182/blood.v120.21.4330.4330","mag":"2582299884"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v120.21.4330.4330","doi":"https://doi.org/10.1182/blood.v120.21.4330.4330","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.4330.4330","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103237792","display_name":"Jenny Li","orcid":"https://orcid.org/0000-0003-4119-5310","observed_orcids":["https://orcid.org/0000-0003-4119-5310"]},"institutions":[{"id":"https://openalex.org/I1282927834","display_name":"Cedars-Sinai Medical Center","ror":"https://ror.org/02pammg90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282927834"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jenny Li","raw_affiliation_strings":["Cedars-Sinai Medical Center, Los Angeles, CA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cedars-Sinai Medical Center, Los Angeles, CA, USA,","institution_ids":["https://openalex.org/I1282927834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022211842","display_name":"Mandy L. Gatesman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I72019824","display_name":"Virginia Commonwealth University Medical Center","ror":"https://ror.org/057xmsr27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I72019824"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mandy L Gatesman","raw_affiliation_strings":["Pharmacy Services, Virginia Commonwealth University Medical Center, Richmond, VA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy Services, Virginia Commonwealth University Medical Center, Richmond, VA, USA,","institution_ids":["https://openalex.org/I72019824"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011190326","display_name":"Ashley M. Newland","orcid":"https://orcid.org/0000-0002-0303-8827","observed_orcids":["https://orcid.org/0000-0002-0303-8827"]},"institutions":[{"id":"https://openalex.org/I72019824","display_name":"Virginia Commonwealth University Medical Center","ror":"https://ror.org/057xmsr27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I72019824"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ashley M Newland","raw_affiliation_strings":["Pharmacy Services, Virginia Commonwealth University Medical Center, Richmond, VA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy Services, Virginia Commonwealth University Medical Center, Richmond, VA, USA,","institution_ids":["https://openalex.org/I72019824"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102832893","display_name":"Roy Sabo","orcid":"https://orcid.org/0000-0001-9159-4876","observed_orcids":["https://orcid.org/0000-0001-9159-4876"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Roy T Sabo","raw_affiliation_strings":["Biostatistics, Virginia Commonwealth University, Richmond, VA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Virginia Commonwealth University, Richmond, VA, USA,","institution_ids":["https://openalex.org/I184840846"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013173470","display_name":"Prithviraj Bose","orcid":"https://orcid.org/0000-0002-4343-5712","observed_orcids":["https://orcid.org/0000-0002-4343-5712"]},"institutions":[{"id":"https://openalex.org/I184840846","display_name":"Virginia Commonwealth University","ror":"https://ror.org/02nkdxk79","country_code":"US","type":"education","lineage":["https://openalex.org/I184840846"]},{"id":"https://openalex.org/I4390039382","display_name":"VCU Massey Comprehensive Cancer Center","ror":"https://ror.org/0173y3036","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prithviraj Bose","raw_affiliation_strings":["Internal Medicine (Hematology/Oncology), Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Internal Medicine (Hematology/Oncology), Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, USA","institution_ids":["https://openalex.org/I184840846","https://openalex.org/I4390039382"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5011190326","https://openalex.org/A5022211842","https://openalex.org/A5102832893","https://openalex.org/A5103237792"],"corresponding_institution_ids":["https://openalex.org/I1282927834","https://openalex.org/I184840846","https://openalex.org/I72019824"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.37945049,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"120","issue":"21","first_page":"4330","last_page":"4330"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14078","display_name":"Multiple and Secondary Primary Cancers","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/secondary-acute-myeloid-leukemia","display_name":"secondary acute myeloid leukemia","score":0.996999979019165},{"id":"https://openalex.org/keywords/therapy-related-acute-myeloid-leukemia","display_name":"therapy-related acute myeloid leukemia","score":0.8410000205039978},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9760000109672546},{"id":"https://openalex.org/keywords/idarubicin","display_name":"idarubicin","score":0.9279999732971191},{"id":"https://openalex.org/keywords/7-3-chemotherapy","display_name":"7+3 induction chemotherapy","score":0.8980000019073486},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.8190000057220459},{"id":"https://openalex.org/keywords/fludarabine","display_name":"fludarabine","score":0.9290000200271606},{"id":"https://openalex.org/keywords/filgrastim","display_name":"filgrastim","score":0.9100000262260437},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.8849999904632568},{"id":"https://openalex.org/keywords/neutrophil-recovery","display_name":"neutrophil recovery","score":0.6919999718666077},{"id":"https://openalex.org/keywords/length-of-hospital-stay","display_name":"length of hospital stay","score":0.6439999938011169},{"id":"https://openalex.org/keywords/infection-risk","display_name":"infection risk","score":0.3479999899864197},{"id":"https://openalex.org/keywords/alkylating-agents","display_name":"alkylating agents","score":0.5370000004768372}],"concepts":[{"id":"https://openalex.org/C2776730729","wikidata":"https://www.wikidata.org/wiki/Q1392130","display_name":"Flag (linear algebra)","level":3,"score":0.8399161696434021},{"id":"https://openalex.org/C2779117419","wikidata":"https://www.wikidata.org/wiki/Q1063862","display_name":"Idarubicin","level":4,"score":0.8175604343414307},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.7860981225967407},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6729910373687744},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6449700593948364},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.6077029705047607},{"id":"https://openalex.org/C2776611710","wikidata":"https://www.wikidata.org/wiki/Q16888295","display_name":"Induction chemotherapy","level":3,"score":0.5756653547286987},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5735986232757568},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47359874844551086},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.4115745723247528},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4097449779510498},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3966146409511566},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3707456588745117},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.08480778336524963},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.07869774103164673},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C202444582","wikidata":"https://www.wikidata.org/wiki/Q837863","display_name":"Pure mathematics","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C136119220","wikidata":"https://www.wikidata.org/wiki/Q1000660","display_name":"Algebra over a field","level":2,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v120.21.4330.4330","doi":"https://doi.org/10.1182/blood.v120.21.4330.4330","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.4330.4330","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W579085835","https://openalex.org/W2807016439","https://openalex.org/W4393163876","https://openalex.org/W4200311099","https://openalex.org/W179444810","https://openalex.org/W92544696","https://openalex.org/W4389219020","https://openalex.org/W4405042995","https://openalex.org/W3006040620","https://openalex.org/W2382214347"],"abstract_inverted_index":{"Abstract":[0,1],"4330":[2],"Objective:":[3],"Acute":[4],"myeloid":[5],"leukemia":[6,261],"(AML)":[7],"that":[8,21],"arises":[9],"from":[10,374],"an":[11,76,135],"antecedent":[12],"hematologic":[13],"disorder":[14],"(most":[15],"often":[16],"myelodysplastic":[17],"syndrome,":[18],"MDS)":[19],"or":[20,53,233,239,249,397],"is":[22,81,157,527],"related":[23],"to":[24,84,93,165,177,301,309,344,451,511,544],"prior":[25,236],"chemotherapy":[26,72],"(therapy-related":[27],"AML,":[28,132],"t-AML)":[29],"carries":[30],"a":[31,410,425,448],"poor":[32],"prognosis.":[33],"Secondary":[34,277],"AML":[35,64,80,146,216,372],"occurs":[36],"in":[37,44,96,112,123,130,169,191,262,350,359,379,392,476],"16\u201350%":[38],"of":[39,46,59,99,139,183,212,254,289,295,371,428,430,496,509,542],"patients":[40,47,60,113,124,192,214,341,491],"with":[41,50,61,69,114,125,193,215,231,258,368,409,447,455,492],"MDS":[42,128,232,375],"and":[43,129,133,181,187,208,243,283,293,299,320,347,480,507,520],"<5%":[45],"previously":[48],"treated":[49],"alkylating":[51,237],"agents":[52,238],"topoisomerase":[54,240],"II":[55,241],"inhibitors.":[56],"Although":[57],"50\u201370%":[58],"de":[62],"novo":[63],"achieve":[65],"complete":[66],"remission":[67],"(CR)":[68],"conventional":[70],"induction":[71,101,189,275,488],"(i.e.,":[73],"cytarabine":[74],"plus":[75],"antracycline,":[77],"\u201c7+3\u201d),":[78],"secondary":[79,115,145,194,255,493,521],"more":[82,377],"resistant":[83],"such":[85,103],"treatment":[86,253,366],"(40\u201350%":[87],"CR":[88,137,272,393],"rate).":[89],"This":[90],"has":[91,120,134],"led":[92],"the":[94,179,271,351,364,369,380,401,503,515,536],"use":[95],"some":[97],"centers":[98],"alternative":[100],"regimens":[102,190],"as":[104,486],"FLAG":[105,117,166,184,246,381,442,481],"(fludarabine,":[106],"cytarabine,":[107],"filgrastim)":[108],"\u00b1":[109,118,167,185,247,382,415,420,434,438,443,458,463,482],"idarubicin":[110],"(Ida)":[111],"AML.":[116,195,256,494],"Ida":[119,168,186,248,383,444,483],"been":[121],"used":[122,142,308,325,485],"relapsed,":[126],"high-risk":[127],"relapsed/refractory":[131],"overall":[136],"rate":[138,273],"33%":[140],"when":[141,484],"first-line":[143],"for":[144,251,326,490,517],"(Clavio":[147],"M":[148],"et":[149],"al.":[150],"Leuk":[151],"Lymphoma":[152],"2001":[153],"Jan;":[154],"40(3\u20134):305-13).":[155],"There":[156,354,387],"currently":[158],"no":[159,356,389,474],"published":[160],"data":[161],"directly":[162],"comparing":[163],"7+3":[164,188,250,406,456,479],"this":[170,469,497],"setting.":[171],"The":[172,267],"present":[173],"study":[174,498],"was":[175,202,270,307,407,445],"undertaken":[176],"compare":[178,310],"effectiveness":[180],"safety":[182],"Methods:":[196],"A":[197,523],"retrospective":[198,470,501],"medical":[199],"record":[200],"review":[201],"conducted":[203],"between":[204,316,363,400,478,514],"January":[205],"1,":[206],"2007":[207],"September":[209],"30,":[210],"2011":[211],"all":[213],"aged":[217],"\u226518":[218],"years":[219],"seen":[220],"at":[221],"our":[222],"institution":[223],"who":[224],"had":[225,234],"either":[226,245],"cytogenetic":[227],"abnormalities":[228],"commonly":[229],"associated":[230,408,446],"received":[235,244],"inhibitors,":[242],"initial":[252,487],"Patients":[257],"chronic":[259],"myelogenous":[260],"blast":[263],"crisis":[264],"were":[265,279,324,338,342,348,355,388],"excluded.":[266],"primary":[268,519],"outcome":[269],"after":[274],"chemotherapy.":[276],"outcomes":[278,312,328],"30-day":[280,395],"mortality,":[281,396],"hospital":[282,398],"intensive":[284],"care":[285],"unit":[286],"(ICU)":[287],"length":[288],"stay":[290],"(LOS),":[291],"sources":[292],"types":[294],"infections,":[296],"antibiotic":[297,431],"usage,":[298],"time":[300,450],"neutrophil":[302,333,452],"recovery.":[303],"Fisher's":[304],"exact":[305],"test":[306],"categorical":[311],"(CR,":[313],"documented":[314],"infections)":[315],"groups.":[317],"Kaplan-Meier":[318],"curves":[319],"corresponding":[321],"log-rank":[322],"tests":[323],"time-to-event":[327],"(hospital":[329],"stay,":[330],"ICU":[331,412],"days,":[332,422,465],"recovery).":[334],"Results:":[335],"291":[336],"charts":[337],"reviewed.":[339],"48":[340],"found":[343,473],"be":[345,533],"eligible":[346],"included":[349],"final":[352],"analysis.":[353],"significant":[357,390],"differences":[358,391,513],"baseline":[360],"demographic":[361],"characteristics":[362],"two":[365,402],"groups,":[367],"exception":[370],"transformation":[373],"being":[376],"prevalent":[378],"group":[384],"(Table":[385,404],"I).":[386],"rates,":[394],"LOS":[399,413],"groups":[403,516],"II).":[405],"shorter":[411,449],"(0.2":[414],"0.7":[416],"days":[417,429,460],"vs":[418,436,461],"2.3":[419],"6.8":[421],"p=0.04)":[423],"but":[424],"greater":[426],"number":[427],"therapy":[432,489],"(56.7":[433],"36.3":[435],"33.6":[437],"31.1,":[439],"p=0.03),":[440],"while":[441],"recovery":[453],"compared":[454],"(20.6":[457],"4.4":[459],"25.8":[462],"7.9":[464],"p=0.01).":[466],"Conclusion:":[467],"In":[468],"study,":[471],"we":[472],"difference":[475],"efficacy":[477],"Limitations":[495],"include":[499],"its":[500],"nature,":[502],"small":[504],"sample":[505],"size":[506],"lack":[508],"power":[510],"detect":[512],"both":[518],"outcomes.":[522],"prospectively":[524],"designed":[525],"trial":[526],"warranted":[528],"before":[529],"one":[530],"regimen":[531],"can":[532],"recommended":[534],"over":[535],"other.":[537],"Disclosures:":[538],"No":[539],"relevant":[540],"conflicts":[541],"interest":[543],"declare.":[545]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2017-02-03T00:00:00"}